Drug intelligence / Profile preview

relacorilant + nab-paclitaxel + gemcitabine

Development stage: Unknown
Lead developer: Corcept Therapeutics
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Relacorilant + nab-paclitaxel + gemcitabine is a combination therapy regimen under investigation for the treatment of metastatic pancreatic cancer. The combination includes relacorilant, a selective glucocorticoid receptor (GR) antagonist developed by Corcept Therapeutics, alongside the standard-of-care chemotherapeutic agents nab-paclitaxel (an albumin-bound microtubule inhibitor) and gemcitabine (a nucleoside metabolic inhibitor). Relacorilant is designed to block the activity of cortisol at the GR, which is hypothesized to prevent cortisol-mediated anti-apoptotic signaling in tumor cells, thereby sensitizing them to the cytotoxic effects of chemotherapy. This triplet regimen is currently being evaluated in the Phase 2 TRIDENT clinical trial for patients with metastatic pancreatic ductal adenocarcinoma.

Other names: CORT125134 + nab-paclitaxel + gemcitabine

Targets

TUBB (Tubulin (alpha and beta subunits))DNA polymerase familyRNR (Ribonucleotide reductase)CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)GR (Glucocorticoid receptor)ABCB1 (P-glycoprotein)CYP3A4 (Cytochrome P450 3A4)

Beyond the preview

Go deeper on relacorilant + nab-paclitaxel + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on relacorilant + nab-paclitaxel + gemcitabine.

Explore the full profile